Ironwood Pharmaceuticals officer plans $32.3K share sale

Available on EDGAR 11/13/2026 - 04:07 PM EST Accepted by SEC EDGAR 11/13/2026 - 04:06 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ironwood Pharmaceuticals Inc. (IRWD) officer Tammi L. Gaskins reported a planned sale of 6,666 Class A common shares, with an aggregate market value of $32,330.10 and an approximate sale date of November 16, 2026. The notice says the shares are to cover taxes from vesting stock awards. The shares were acquired through an 18,000-share restricted stock unit award granted December 11, 2024, under the company’s Amended and Restated 2019 EIP, subject to vesting requirements.

Key Figures

Class A common shares to be sold: 6,666 shares Aggregate market value: $32,330.10 Restricted stock unit award: 18,000 shares

3 metrics

Class A common shares to be sold 6,666 shares Planned sale; approximate sale date November 16, 2026

Aggregate market value $32,330.10 Shares listed for sale

Restricted stock unit award 18,000 shares Granted December 11, 2024, subject to vesting requirements

Key Terms

Restricted Stock Unit award, vesting requirements

2 terms

Restricted Stock Unit award financial

"Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 EIP"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

vesting requirements financial

"subject to vesting requirements"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IRWD shares did Tammi Gaskins plan to sell?

Tammi L. Gaskins, an officer of Ironwood Pharmaceuticals Inc., reported a planned sale of 6,666 Class A common shares, with an aggregate market value of $32,330.10 and an approximate sale date of November 16, 2026. The notice says the shares are to cover taxes from vesting stock awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002061679
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IRONWOOD PHARMACEUTICALS INC
SEC File Number	001-34620
Address of Issuer	100 SUMMER STREET, SUITE 2300 BOSTON MASSACHUSETTS 02110
Phone	617-621-7722
Name of Person for Whose Account the Securities are To Be Sold	Gaskins Tammi L
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	Etrade Securities LLC 3 Edison Drive Alpharetta GA 30005	6666	32330.10	165550760	11/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common Stock	12/11/2024	Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 EIP, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			18000	12/11/2024	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Shares sold to cover taxes from the vesting of stock awards granted by the Issuer.
Date of Notice	11/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Tammi Gaskins
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)